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Objectives: Ongoing developments in design have improved the outlook for
left-ventricular assist device (LVAD) implantation as a therapy in end-stage heart failure.
Nevertheless, early cost-effectiveness assessments, based on first-generation devices,
have not been encouraging. Against this background, we set out (i) to examine the
survival benefit that LVADs would need to generate before they could be deemed
cost-effective; (ii) to provide insight into the likelihood that this benefit will be achieved;
and (iii) from the perspective of a healthcare provider, to assess the value of discovering
the actual size of this benefit by means of a Bayesian value of information analysis.
Methods: Cost-effectiveness assessments are made from the perspective of the
healthcare provider, using current UK norms for the value of a quality-adjusted life-year
(QALY). The treatment model is grounded in published analyses of the Randomized
Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure
(REMATCH) trial of first-generation LVADs, translated into a UK cost setting. The
prospects for patient survival with second-generation devices is assessed using Bayesian
prior distributions, elicited from a group of leading clinicians in the field.
Results: Using established thresholds, cost-effectiveness probabilities under these priors
are found to be low (∼.2 percent) for devices costing as much as £60,000. Sensitivity of
the conclusions to both device cost and QALY valuation is examined.
The authors are indebted to Reynolds Delgado III, MD, William Holman, MD, William Pierce MD, Evgenij Potapov MD, and Branislav Radovancevic MD
for their individual and collective contributions to the prior assessments in section 4. A.J.G., J.G., and R.J.L. acknowledge support of this work through the
MATCH Programme (EPSRC Grant GR/S29874/01), although the views expressed are entirely theirs.
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Conclusions: In the event that the price of the device in use would reduce to £40,000, the
value of the survival information can readily justify investment in further trials.
Keywords: Heart assist devices, Cost-effectiveness, Value of information, Bayesian
analysis, Prior elicitation
Heart failure (HF) is a serious disease with prevalence rates
in Europe and the United States ranging from .3 percent
to 2 percent (15). A recent estimate has 5 million cases in
the United States alone (2). Patients in end-stage heart fail-
ure (ESHF) have a poor prognosis, with 1-year mortality of
50 percent or more (12;37;50). Approximately 100,000 new
cases of ESHF each year in the United States could benefit
from advanced therapeutic intervention (30). In England and
Wales, there are 10,000–15,000 new ESHF cases annually
(11). Heart transplant (HT) offers the best outlook in terms
of length and quality of life (20;25;34) but is unavailable in
many cases (16;26;40). Long-term treatment with a left ven-
tricular assist device (LVAD) was sanctioned by the US Food
and Drug Administration (FDA) in 2002 (17) and is widely
regarded as the most promising alternative for patients not
eligible for HT (28;44;46).
There are several types of implantable LVADs. The so-
called first-generation devices generate pulsatile flow us-
ing a displacement pump. Second-generation pumps pro-
vide continuous (nonpulsatile) blood flow and address
some of the shortcomings of the first-generation devices
(11;14;34;44;48). The only completed randomized con-
trolled trial (RCT) of LVADs as destination therapy (the
Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure [REMATCH] trial)
(42) reported convincing evidence of efficacy and effective-
ness for a first-generation device, but has led to unfavorable
assessments of the cost-effectiveness of the treatment com-
pared with optimal medical management (OMM). Based on
REMATCH data, one study (4) estimated that LVADs are
cost-effective at valuations of more than US$800,000 per
quality-adjusted life-year (QALY), a figure well in excess
of UK norms (39) and probably too expensive even for the
richest healthcare provider.
Advances in pump technology (27), and improvements
in the clinical management of LVAD patients (30) can be ex-
pected to improve the survival prospects for LVAD patients,
perhaps to the extent where these improvements would out-
weigh the high cost of treatment. Second-generation nonpul-
satile pumps offer particularly good prospects and are the
subject of several ongoing surgical trials (27). Further ran-
domized trials are contemplated, which might throw further
light on the benefits of the therapy. At the same time, innova-
tion in pump technology continues unabated (47), although
doubts remain whether the so-called third-generation pumps
can generate significant additional health benefit (24).
In this study, our purpose is threefold: (i) to examine
the survival benefit that LVADs would need to generate to be
cost-effective compared with OMM; (ii) to provide insight
into the likelihood that this benefit will be achieved; and
(iii) from the perspective of a healthcare provider, to assess
the value of discovering the actual size of this benefit using
a Bayesian value of information analysis (9;10). Our aims
are addressed through a health–economic model for LVAD
therapy based on the REMATCH experience translated into
a UK cost setting. In the cost analysis, the price of the device
itself is the most significant uncertainty, especially as it may
well fall in response to future market growth (13;22). Ex-
pectations surrounding future patient survival are captured
probabilistically using Bayesian prior distributions elicited
from a group of leading experts.
A MODEL FOR LVADS AS DESTINATION
THERAPY
The patient population is defined by the entry criteria to the
REMATCH trial (41;42). It comprises adults with chronic
ESHF not eligible for HT, and with ongoing symptoms of
New York Heart Association class IV. This population is
modeled as a homogeneous group, disregarding the possible
impact of prior risk factors, such as patient age. The oper-
ation itself is taken as the starting point for both costs and
patient survival, and the modeled pathway terminates with
death. Waiting time for the operation to implant an LVAD is
not considered here. The operation is followed by a period of
“initial hospitalization,” which terminates when the patient is
discharged. Subsequently, patients receive ongoing medical
care based on regular outpatient visits, and that care may
include periods of readmission to the hospital. The treatment
cost is taken to include the cost of the device, the cost of
initial hospitalization (including all costs associated with the
operation), and the ongoing costs of care until the death of the
patient. The first two components are treated as fixed costs
(i.e., independent of survival time) and the ongoing care cost
as proportional to the patient’s survival time after discharge.
In the REMATCH trial, the initial hospitalization costs for
patients successfully discharged from the hospital were
substantially less than for those who were never discharged,
both in aggregate and also when converted to a daily rate
(35), a finding confirmed by subsequent experience (31). In
the model, LVAD patients are divided into two groups: “Suc-
cesses,” those who are successfully discharged; and “Fail-
ures,” who never leave the hospital. The ratio of average hos-
pitalization costs for Successes and Failures is taken from the
REMATCH experience as 1:2.3 per patient (35). The overall
average hospitalization costs derive from UK estimates.
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Improvements in LVAD therapy will increase both the
patients’ overall life expectancy and the proportion of treat-
ment Successes. An increase in the latter is automatically
associated with reduced hospitalization costs per patient.
Similarly, improvements in patient survival will affect
the costs of ongoing medical care. The obvious effect is to
increase them. Nevertheless, it is likely that recognized im-
provements in long-term survival will impact on follow-up
protocols and also lead to a reduction in the proportion of sur-
vival time spent in hospital readmissions. These effects are
modeled by allowing both the frequency of outpatient visits
and the fraction of time in readmission to be inversely pro-
portional to the average life expectancy among the treatment
Successes. As a result, the outpatient interval ranges from
7 weeks (44) to 3 months under an optimistic life expectancy
Table 1. Sources for Model Parameters
Mean survival
LVAD Successes µS Assessed from expert priors;
REMATCH data consistent
with µS = 30 to 40 months
(see Figure 1)
LVAD Failures 2 months (35)
OMM 7.8 months (4)
Proportion of LVAD treatment Failures π Assessed from expert priors.
REMATCH data has
π = .33 (35)
Utilities
LVAD .81 (33)
OMM .55 (33)
Initial hospitalization cost (including
theater costs, excluding device cost)
LVAD Successes £27,821 Average cost £39,877 (11),
apportioned between
Successes and Failures in ratio
observed in the REMATCH
trial (35)
LVAD Failures £63,989
Length of Initial hospitalization (LVAD
Successes)
35 days (35)
LVAD/OMM Hospital readmission cost,
per month in the hospital
£16,170 (11)
Fraction of time in the hospital post–initial
discharge (LVAD)
4 ÷ µS Assumed proportional to death
rate from HF (see text),
calibrated to REMATCH value
(35) (.10) at µS = 40 months
Fraction of time in the hospital (OMM) .15 (42)
Outpatient cost per visit (LVAD and OMM) £99 (11)
LVAD Outpatient visits (per month out of
the hospital)
25 ÷ µS Assumed proportional to death
rate from HF (see text),
calibrated to value in (44)
(every 6–8 weeks) at µS =
40 months
OMM Outpatient visits (per month out of
the hospital)
.619 Same rate as for LVAD in (44),
equivalence supported by (11)
Discount rate 3.5% p.a. (23)
LVAD, left ventricular assist device; REMATCH, Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure
(REMATCH); OMM, optimal medical management; HF, heart failure; p.a., per annum.
of 80 months postimplantation in the Success group. The
time spent in readmission ranges from 10 percent (42) to an
optimistic 5 percent of the time after initial discharge.
Table 1 summarizes the model parameters. Cost esti-
mates rely heavily on the recent study by Clegg and others
(11). The cost of the device is treated as an exceptional case.
It was around US$60,000 for a first-generation device in the
REMATCH trial (42), whereas Siegenthaler and colleagues
(44) paid GB£60,000 for a second-generation device. In the
future, the price may be affected by technological develop-
ments and changes in uptake. This uncertainty is treated here
by presenting results over a range of device costs.
The incremental cost-effectiveness of LVAD therapy is
defined relative to OMM, which entails regular outpatient
visits and may include periods of admission to the hospital.
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Figure 1. Actual and modelled survival of patients in the REMATCH trial. OMM, optical medical management. (Data from
ref. 4 with revised 24 month LVAD estimate from Park et al. [36]).
The outpatient interval is taken as 7 weeks (44), and the hos-
pitalization fraction as 15 percent (4). Daily hospitalization
costs are assumed the same as those under LVAD.
Patient Survival
Patient survival under OMM is described by the exponen-
tial (constant hazard) distribution (4) in Figure 1, with mean
survival suggested by the REMATCH trial (4). For LVAD
patients, death can occur either during initial hospitalization
(treatment Failure) or following discharge (treatment Suc-
cess). Separate exponential survival distributions are used
for Successes and Failures. The mean survival time for a
Failure was taken as 2 months (35). This timing is the aver-
age length of stay in the hospital for a patient who does not
survive the initial hospitalization, and is regarded as fixed.
The key parameters for determining the life expectancy of
patients under LVAD are as follows: π , the proportion of
Failures; and µS , the mean survival time for Successes.
In the REMATCH trial of first-generation devices, π is
estimated as .33 (=17/51) (35), and a good fit to the survival
distribution reported to the FDA (3) is obtained by taking
µS = 35 months, as in Figure 1. Subsequent improvements
in survival under LVAD (30;36) can be modeled by increasing
µS and/or by reducing π .
The mean survival time is modeled as 2π + µS(1 −
π ). Provided that Successes account for more than half the
patients, the median survival time is (approximately) m =
µS loge{2(1 − π )}.
In this model, the probability of death in the hospi-
tal within 30 days of the LVAD implantation is given by
0.39 ×π . Hence, π is proportional to a clinical “periopera-
tive mortality rate,” whereas the value of µS is just the life
expectancy of successfully treated patients.
THE FUTURE COST-EFFECTIVENESS OF
LVAD THERAPY
LVAD therapy can be considered cost-effective compared
with OMM if the (discounted) value of the additional QALYs
it generates exceeds the additional (discounted) treatment
costs incurred. The analysis is conducted under valuations of
a QALY derived from current UK norms (39). The model can
then be used to identify threshold values of the survival pa-
rameters under which the therapy is just cost-effective. The
results are shown in Figure 2 for devices at several differ-
ent prices, including (for reference purposes) a hypothetical
device that would cost nothing at all.
For ease of clinical interpretation, the parameter plot-
ted on the vertical axis is the overall median survival under
LVAD therapy rather than µS , the mean survival time among
treatment Successes. For a given device price, a point on the
curve corresponds to a combination of survival parameters
at which the incremental cost-effectiveness ratio (ICER) for
LVAD compared with OMM is exactly equal to the hypoth-
esized value of a QALY. Points above or to the right of the
curve have ICERs lower than the QALY valuation and corre-
spond to an LVAD therapy that is cost-effective. Points below
or to the left do not give a cost-effective result.
The survival experience of LVAD patients in the RE-
MATCH trial corresponds to a median survival of 408 days
(42)—or 13.4 months—combined with a Failure proportion
π of .33 (35). From Figure 2, it is clear that this could
not represent a cost-effective therapy at current UK QALY
valuations at any positive value of the device cost. This con-
clusion concurs with that suggested by the model in one study
(4), despite using more favorable UK treatment costs in the
current work. It is clear that the cost-effectiveness of the
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Figure 2. Cost-effectiveness thresholds under different assumptions about device cost and quality-adjusted life-year (QALY)
valuations, with contours of the joint prior distribution superimposed. Under the model assumptions, the curves show combi-
nations of survival parameters under which left vertical assist device (LVAD) therapy would be just cost-effective compared to
optical medical management (OMM) at £30,000 per QALY (a) and £40,000 per QALY (b). The inner shaded region represents
50 percent and the entire shaded region 90 percent of the prior probability.
therapy will depend on substantial improvements in survival
being achieved by later generations of devices.
PRIOR ASSESSMENTS OF LVAD
SURVIVAL PARAMETERS
It is difficult to give precise estimates of the survival bene-
fits of the latest generations of LVADs. The REMATCH trial
is the only RCT to report results for LVADs as destination
therapy, and these results were for first-generation pulsatile
devices. While further results are awaited, a way forward can
be found by exploring the expert opinions of those cardiac
specialists best able to assess the likely effectiveness of the
current generation of devices. This assessment was done by
eliciting Bayesian prior distributions for the survival param-
eters. The priors were used in two ways: first to estimate
the probability that LVADs will turn out to be cost-effective
when their full benefits are known; and second in a Bayesian
value-of-information analysis (32) to arrive at a prospective
monetary valuation of the information that a future trial might
uncover.
A group of five leading clinicians was assembled at the
51st annual conference of the American Society for Artificial
Internal Organs (ASAIO) in Washington (2005). All had sub-
stantial experience with the use of current generation LVADs
for the treatment of ESHF. The elicitation procedure was that
described in Garthwaite et al. (21). It was applied to obtain
priors for the perioperative (30-day) mortality and the over-
all median survival for LVAD in patients fulfilling the entry
criteria to the REMATCH trial: New York Heart Associa-
tion (NYHA) class IV/American College of Cardiology and
the American Heart Association (ACC-AHA) class D, with
contraindications rendering them ineligible for cardiac trans-
plant. For each parameter, the procedure entails a discussion
of a small number of quantiles of the prior distribution among
the group, feeding back a computer-generated density func-
tion in real time, which is then amended as necessary until a
shape satisfactory to the whole group is obtained. Consensus
was achieved for both parameters. For median survival, the
consensus density occupied the range 12–40 months, was
centered on 25 months, and attached a prior probability of
.22 to the range 12–20 months and a prior probability of .23
to the range 30–40 months. The density for 30-day mortality
occupied the range 3–16 percent, was centered on 10 percent,
and attached prior probabilities of .22 and .25, respectively,
to the ranges 3–8 percent and 12–16 percent. These re-
sults are similar to those obtained during 2005 in separate
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elicitations from six individual clinicians in the United King-
dom as described by one of the authors (J.G.) in a forthcoming
study (unpublished, 2007). The individual elicitations furnish
a useful check on those from the Washington group but have
not been formally incorporated into the current analysis.
The elicited densities were combined to form a joint prior
density for the proportion of Failures (π ) and the median sur-
vival (m). Contours of the joint density are present in Figure
2a and 2b. They were derived assuming prior independence
between the proportion of Failures and the survival prospects
for treatment Successes—that is, treating π and µS as sta-
tistically independent parameters. Details of the calculations
are available on request from the corresponding author.
COST-EFFECTIVENESS PROBABILITIES
AND THE VALUE OF FURTHER
INFORMATION
In Figure 2a and 2b, the probability assigned to the area
above and to the right of a threshold curve can be interpreted
as the chance, as perceived by leading clinical experts, that
the device will turn out to be cost-effective at a specified
QALY valuation. Results of this kind over a range of LVAD
costs are included in Table 2.
The tabulated cost-effectiveness probabilities confirm
that LVAD therapy is extremely unlikely to be cost-effective
at current UK QALY valuations of around £30,000 if the
device costs as much as the £60,000 incurred by Siegenthaler
Table 2. Cost-Effectiveness Results over a Range of LVAD Costs
Value of Free Device @ Device @ Device @ Device @
QALY device £20,000 £40,000 £60,000 £80,000
£20,000 ENB −£10,952 −£30,952 −£50,952 −£70,952 −£90,952
EVI £946 £5 <£1 <£1 <£1
C/E Prob. .14 <.001 <.001 <.001 <.001
£25,000 ENB +£1,141 −£18,859 −£38,859 −£58,859 −£78,859
EVI £4188 £577 £6 £0 <£1
C/E Prob. .48 .08 .002 <.001 <.001
£30,000 ENB +£13,234 −£6,766 −£26,766 −£46,766 −£66,766
EVI £1,064 £3,303 £395 £6 <£1
C/E Prob. .84 .28 .05 .002 <.001
£35,000 ENB +£25,327 +£5,327 −£14,673 −£34,673 −£54,673
EVI £325 £4,065 £2,255 £294 £6
C/E Prob. .96 .59 .19 .04 .002
£40,000 ENB +£37,420 +£17,420 −£2,580 −£22,580 −£4,580
EVI £132 £1,438 £6,497 £1,645 £231
C/E Prob. .98 .83 .39 .13 .03
£45,000 ENB +£49,514 +£29,514 +£9,514 −£10,486 −£30,486
EVI £64 £562 £4,177 £4,762 £1,260
C/E Prob. .99 .94 .65 .28 .10
Note. Given are the following: (i) the expected value of the net benefit per patient under LVAD therapy (ENB), (ii) the expected value
of acquiring perfect information about LVAD survival parameters (EVI), and (iii) the probability that LVAD therapy is cost-effective
compared to OMM (C/E Prob.). Results are computed using expert priors for the survival parameters in the model described in section 2,
with UK treatment costs from Table 1. Several plausible device costs and QALY valuations derived from UK practice are represented.
LVAD, left ventricular assist device; QALY, quality-adjusted life-years.
and colleagues (44). In fact the cost-effectiveness probability
is no more than 84 percent even in the (implausible) case
that the device costs nothing at all! Nevertheless, the figures
are not inconsistent with an ultimately favorable assessment
of LVAD therapy if the cost of the device were to fall in the
future.
The subjective nature of the cost-effectiveness probabili-
ties means that healthcare providers may view them with little
more than academic interest – even in systems (such as the
UK National Health Service) where economic evaluations
form an explicit component of reimbursement decisions. It
is generally recognized that the highest grade of evidence
for such decisions is supplied by the results of RCTs, and
it is therefore unlikely that an answer to the primary ques-
tion of whether to reimburse LVAD treatment as destination
therapy would be given on the basis of the prior probabilities
reported here, however eminent the clinical source. Never-
theless, the absence of a definitive evidence base means that
any decision to carry out an RCT will be taken in the light
of an opinion about its possible benefits that must be, at least
in part, speculative. It has been argued that Bayesian prior
distributions are the natural vehicle for the quantification of
such opinion (29;43;45). Here, the principal area of scien-
tific uncertainty concerns the likely survival benefits of LVAD
therapy. Thus, prior distributions for the survival parameters
have a role to play when addressing the secondary question of
whether further trials in this area should be conducted. In fact,
they can be used to generate a formal value of information
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analysis, following the methods advocated in several reports
(6;7;18).
The value of information analysis proceeds by exam-
ining the likely change in the estimate of net benefit to
be expected from LVAD therapy induced by the results of
a very large (fully informative) trial. Here, net benefit is
defined as the discounted value of the extra QALYs asso-
ciated with the therapy compared with OMM, net of any
additional (discounted) costs. The rows labeled ENB (i.e.,
expected net benefit) in Table 2 contain current estimates,
that is, the net benefit per patient treated averaged over the
elicited prior distribution for the survival parameters. A pos-
itive value of ENB indicates that LVAD therapy is estimated
to be cost-effective under the best information currently
available; a negative ENB, that it is estimated to be cost-
ineffective.
Thus in theory, an ENB from Table 2 could be used
to inform an interim reimbursement decision for a second-
generation LVAD. Nevertheless, the possibility remains that
the wrong decision will have been taken. For example, at the
£30,000 threshold, a decision not to reimburse a device cost-
ing £20,000 will be taken knowing that there is a 28 percent
chance that the therapy will be cost-effective, because of the
uncertainties surrounding the survival parameters. For this
reason, it may be sensible to sponsor an investigation—for
example, an RCT—to refine the estimates of these parame-
ters so that a better-informed reimbursement decision can be
taken. Taking the perspective of an insurance provider, ex-
penditure on such an investigation cannot be justified unless
it is outweighed by the likely benefits that would be attached
to updating the reimbursement decision. Under the precepts
of value-of-information analysis, these benefits are identified
with the opportunity loss associated with taking the wrong re-
imbursement decision in the first place. For example, suppose
it becomes apparent after a trial that the device is associated
with a cost-effective destination therapy. (This finding could
happen if the true values of the survival parameters were at the
optimistic end of the prior distribution.) Then the opportunity
loss associated with the (incorrect) decision not to reimburse
would be equal to the true net benefit of the therapy, which
is now known to be positive. Expenditure on the trial would
then have been justified provided its cost per patient affected
had been no greater than the size of the revised net benefit. On
the other hand, the trial might simply reveal that the original
impression that the device is not cost-effective was correct.
In this case, the trial will have no impact on the original
decision and will have had no value in terms of avoided op-
portunity loss. In practice, such calculations cannot be made
in advance, because it is not known what the results of a trial
will reveal. Instead, the expected value of the opportunity
loss can be computed using currently available prior distri-
butions for the survival parameters. This quantity is known
as the “expected value of perfect information” (denoted by
EVI in Table 2) (38). As expected, it turns out that EVI
is greatest when the current reimbursement decision is least
clear-cut as reflected by cost-effectiveness probabilities close
to .5.
IMPLICATIONS FOR FUTURE TRIALS
The EVI values in Table 2 are computed on a per patient
basis. The expected value of the information to the health-
care provider is obtained by aggregation over an appropri-
ate patient population during the anticipated lifetime of the
technology, or over a time horizon chosen for political or
accounting reasons. For England and Wales, it has been esti-
mated that there are up to 15,000 new cases of ESHF annu-
ally. Taking these cases as the patient population, then, over
a time horizon of N years, the total (discounted) EVI will
be
(
1 + 1
1 + r +
1
(1 + r)2 + · · · +
1
(1 + r)N−1
)
× (EVI per patient) × 15,000,
where the discount rate is 100r percent per annum. At
3.5 percent over N = 5 years, this value is 4.67 × (EVI per
patient) × 15,000.
For example, suppose the price of the device is the
£60,000 paid by Siegenthaler et al. (44). Then, at £30,000 per
QALY, the expected value of gaining complete information
about the survival parameters for patients over the next 5
years is 4.67 × £6 × 15,000 = £420,000. Over 10 years, the
expected value would be 8.61 × £6 × 15,000 = £775,000.
Both these values are substantially less than the anticipated
costs associated with a meaningful RCT of second-
generation LVADs. On the other hand, a trial of a device with
a long-term price of £40,000 could yield information with
an expected value of 4.67 × £395 × 15,000 = £28 million
over 5 years and 8.61 × £395 × 15,000 = £51 million over
10 years—enough to justify a substantial outlay on an
RCT.
The expected value of information calculation attempts
to place an upper bound on the justifiable cost to the health-
care provider of a further trial when LVAD research is in
competition with other uses to which limited resources can
be put. Hence, it can help to prioritize a research agenda,
and assist in the allocation of resources between research
and direct medical care. Here, it suggests that the costs of a
future LVAD trial could not be recouped over any reasonable
period unless the cost of the device were substantially less
than £60,000, a value that has actually been incurred in a UK
context (44). On the other hand, the report by Clegg and col-
leagues (11) entertains a lower range of device prices (around
£30,000–60,000) based on a submission from a device man-
ufacturer. In any case, reductions in price are not implausible
once the market expands and have been observed for other
medical product (5).
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DISCUSSION
Value of information is used here as a form of sensi-
tivity analysis to explore the decision-value of parameter
uncertainties in a cost-effectiveness model. The focus of our
attention is the uncertainty surrounding the survival benefits
of second-generation LVADs where these are used as destina-
tion therapy in ESHF. The other major source of uncertainty
is the price at which the device can be made available, and
this price is treated as an exogenous variable in our calcu-
lations. It must be emphasized that the relevant price is not
the one that is obtained today, nor even over the next few
months; it is the price at which the device will be sold in fu-
ture, assuming a sizeable market. To a large degree, this price
is under the control of the manufacturing companies and is
difficult to predict without access to commercially sensitive
information. Of course, a reimbursement decision—or even
a decision to sponsor a trial—can be sensibly taken only
when this price is specified, at least within plausible limits.
Then the results presented here can be used to inform these
decision-making processes.
Uncertainty surrounding other parameters in the
model—in particular the treatment costs excluding the cost
of the device—does not figure in our analysis. This strat-
egy is both deliberate and rational. The motivation for the
example in this study is to assess the potential impact on re-
imbursement decisions of future trials designed principally
to uncover the survival benefits of LVADs. The underlying
assumption is that such decisions are informed by a cost-
effectiveness analysis using the best available estimates of
all model parameters, with only informal attention paid to
parameter uncertainties. Following a future trial, the reim-
bursement decision will likewise be taken in the light of the
best available estimates, accompanied by an informal con-
sideration of model sensitivities. Our concern has been to
map the effect on this process of a change in the values of the
best estimates of a small number of (survival) parameters.
Uncertainties in cost parameters make no formal contribu-
tion to this process. This approach has been described as
“partial” value of perfect information analysis, because it
contemplates the effect of eliminating all uncertainty about
only some of the parameters (8;19). In practice, this will not
be achieved by a single trial, however large. Some statistical
uncertainty in the results is unavoidable. Thus, an analysis
based on valuing perfect information places an upper bound
on the justifiable cost of any trial, but without confirming that
any particular trial ought to go ahead. A formal analysis of
the information value in a realistic finite trial can be made
using previously described sample information methods
(1;49).
Our aim has been to explore the case for a new trial of
second-generation LVADs, given the best available current
evidence and clinical opinion. In conclusion, it appears that
such a trial would represent value for money in a UK setting,
assuming a plausible device-cost of around £40,000.
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